PetCaseFinder

Peer-reviewed veterinary case report

New kidney tests and scans for dogs with leishmaniosis

By González, Mario A et al.·Published in Research in veterinary science·2025·Hospital Cl&#xed, Spain·View original on PubMed

PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →

Original publication title: New biomarkers and scintigraphic evaluation of renal function in dogs with canine leishmaniosis.

Species:
dog

Plain-English summary

A 6-year-old dog with canine leishmaniosis (a disease caused by a parasite) was evaluated for kidney function using new blood and urine tests. Researchers found that certain biomarkers in the blood and urine could help determine how advanced the dog's kidney disease was. One specific blood test, called cystatin C, showed great promise for identifying kidney issues early. These findings suggest that these new tests could be useful for veterinarians in monitoring kidney health in dogs with this condition.

People also search for: dog kidney disease leishmaniosis · cystatin C test for dogs · canine leishmaniosis symptoms

Abstract

This study evaluated the utility of new renal biomarkers in canine leishmaniosis (CanL). A total of 6 healthy dogs (CG) and 22 dogs with CanL (LeishVet stage III or GIII (n = 11) and stage IV or GIV (n = 11)) were included. Plasma creatinine, urea, cystatin C (pCysC), and symmetric dimethylarginine were analyzed. In urine, neutrophil gelatinase-associated lipocalin, retinol-binding protein, Tamm-Horsfall protein, and total protein were measured using their ratios with creatinine (uNGAL/c, uRBP/c, uTHP/c, and UPC, respectively). The estimated glomerular filtration rate (eGFR) was assessed by 99mTc-DTPA scintigraphy. All glomerular biomarkers strongly correlated with eGFR and showed statistically significant differences between CanL stages but not with CG, except for pCysC, which was particularly noteworthy for its statistical significance, instilling confidence in its potential use. All tubular biomarkers presented significant differences between GIV and CG; however, only uNGAL/c and uTHP/c differentiated between GIII and CG. Moreover, none could distinguish between the GIII and GIV groups. These data suggest that the new glomerular biomarkers could help determine stages of renal disease in CanL. uNGAL/c and uTHP/C showed advantages in making an earlier diagnosis. Ultimately, pCysC presented tremendous potential, as it was statistically significant for both uses. This research provides valuable information to understand the behavior of these biomarkers in renal disease secondary to CanL.

Find similar cases for your pet

PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.

Search related cases →

Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/40022866/